Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Total Non-Current Liabilities (2016 - 2025)

Sutro Biopharma (STRO) has disclosed Total Non-Current Liabilities for 10 consecutive years, with $304.6 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 10.65% to $304.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $304.6 million through Dec 2025, down 10.65% year-over-year, with the annual reading at $304.6 million for FY2025, 10.65% down from the prior year.
  • Total Non-Current Liabilities hit $304.6 million in Q4 2025 for Sutro Biopharma, up from $295.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $345.5 million in Q1 2025 to a low of $50.6 million in Q1 2021.
  • Historically, Total Non-Current Liabilities has averaged $222.0 million across 5 years, with a median of $292.8 million in 2025.
  • Biggest five-year swings in Total Non-Current Liabilities: dropped 29.44% in 2021 and later surged 242.94% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $88.7 million in 2021, then soared by 113.96% to $189.8 million in 2022, then skyrocketed by 68.3% to $319.4 million in 2023, then grew by 6.74% to $340.9 million in 2024, then dropped by 10.65% to $304.6 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for STRO at $304.6 million in Q4 2025, $295.2 million in Q3 2025, and $292.8 million in Q2 2025.